SREBF1 and metabolic dysfunction-associated steatotic liver disease: Fasting hyperglycemia and increased influx of FFAs, as well as higher levels of ROS and inflammatory cytokines in the liver, stimulate SREBP1/2 in the livers of NAFLD patients and animals, even independent of insulin resistance [64,65,66,67].